Syena, the fourth product company to launch under Replay, is taking on TCR NK cells

GSK drops more cancer programs as it steps away from Lyell, Adaptimmune partnerships

CSO stepping down to join biopharma ‘dream team’ at newly launched Altos

Close to 30 new modality drugs approved in the last five years, and about 50 in registrational trials

How Tmunity’s focus on CMC for its engineered T cell therapies factored into its $75M series B

Two years into its cancer rebuild, GSK's strategy to break into immuno-oncology may soon start to pay off